You are here:

darunavir (Prezista)


Following a full submission

darunavir (Prezista) co-administered with low dose ritonavir and in combination with other antiretroviral medicinal products is accepted within NHS Scotland for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral therapy (ART) naïve adults.

After 48 weeks the combination of darunavir and ritonavir was non-inferior to a standard boosted protease inhibitor regimen in ART naïve adults. The combined regimen was associated with lower incidences of diarrhoea and lipid adverse effects

Drug Details

Drug Name: darunavir (Prezista)
SMC Drug ID: 566/09
Manufacturer: Tibotec (Janssen-Cilag Ltd)
Indication: Human immunodeficiency virus (HIV 1) infection in antiretroviral therapy (ART) naïve adults.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 September 2009